Published in J Biol Chem on February 05, 1986
DNA-nanotube-induced alignment of membrane proteins for NMR structure determination. Proc Natl Acad Sci U S A (2007) 3.29
Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci U S A (2006) 1.73
Characterization of molecular alignment in aqueous suspensions of Pf1 bacteriophage. J Biomol NMR (2001) 1.39
Prediction of charge-induced molecular alignment of biomolecules dissolved in dilute liquid-crystalline phases. Biophys J (2004) 1.38
Liquid crystalline phase of G-tetrad DNA for NMR study of detergent-solubilized proteins. J Am Chem Soc (2008) 1.09
Polyelectrolyte properties of filamentous biopolymers and their consequences in biological fluids. Soft Matter (2014) 0.88
Structural polymorphism correlated to surface charge in filamentous bacteriophages. Biophys J (1992) 0.85
Controlled self-assembly of rodlike bacterial pili particles into ordered lattices. Angew Chem Int Ed Engl (2011) 0.84
Prediction of charge-induced molecular alignment: residual dipolar couplings at pH 3 and alignment in surfactant liquid crystalline phases. Eur Biophys J (2005) 0.82
Biotemplating rod-like viruses for the synthesis of copper nanorods and nanowires. J Nanobiotechnology (2012) 0.82
Criticality in a non-equilibrium, driven system: charged colloidal rods (fd-viruses) in electric fields. Eur Phys J E Soft Matter (2009) 0.78
Induced alignment and measurement of dipolar couplings of an SH2 domain through direct binding with filamentous phage. J Biomol NMR (1999) 0.77
Large-scale arrays of aligned single viruses. Adv Mater (2010) 0.75
An electric-field induced dynamical state in dispersions of highly charged colloidal rods: comparison of experiment and theory. Colloid Polym Sci (2015) 0.75
Rheology and DWS microrheology of concentrated suspensions of the semiflexible filamentous fd virus. Eur Phys J E Soft Matter (2012) 0.75
Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (1999) 36.25
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis (2004) 3.22
Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol (1988) 2.83
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med (1995) 2.30
The challenge of biosimilars. Ann Oncol (2007) 2.28
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Identification of a common antigen of herpes simplex virus bovine herpes mammillitis virus, and B virus. J Virol (1978) 2.16
Interleukin-6 is a prognostic factor in multiple myeloma. Blood (1991) 2.16
A viro-psycho-immunological disease-model of a subtype affective disorder. Pharmacopsychiatry (1998) 2.08
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
Physicochemical properties of the DNA of herpes viruses. Biochim Biophys Acta (1972) 1.86
First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry (1996) 1.83
A simple method for measuring red cell deformability in models of the microcirculation. Blut (1973) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Sequence conservation in field and experimental isolates of Borna disease virus. J Virol (1994) 1.67
Detection of new DNA polymerase genes of known and potentially novel herpesviruses by PCR with degenerate and deoxyinosine-substituted primers. Virus Genes (1999) 1.65
Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet (1997) 1.62
Persistent, tolerant or subacute infection in Borna disease virus-infected rats. J Gen Virol (1983) 1.62
Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension. J Neurosurg Anesthesiol (2000) 1.61
Clp-mediated proteolysis in Gram-positive bacteria is autoregulated by the stability of a repressor. EMBO J (2001) 1.61
Borna disease--neuropathology and pathogenesis. Curr Top Microbiol Immunol (1995) 1.59
Borna disease virus-specific antibodies in patients with HIV infection and with mental disorders. Lancet (1988) 1.57
A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr (2011) 1.52
Peptide linkers lead to modification of liver metabolism and improved tumor targeting of copper-67-labeled antibody fragments. Cancer Biother Radiopharm (2001) 1.51
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.47
Blood pressure and adipose tissue linoleic acid. Res Exp Med (Berl) (1979) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia (2008) 1.42
Immunologic and genetic relationship between herpes simplex virus and bovine herpes mammillitis virus. Intervirology (1974) 1.41
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol (2000) 1.39
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol (2009) 1.39
Specificity of cleavage in replicative-form DNA of bovine herpesvirus 1. J Virol (1988) 1.34
Borna disease in ostriches. Vet Rec (1993) 1.34
Studies on the relatedness of herpes viruses through DNA-RNA hybridization. Biochim Biophys Acta (1972) 1.31
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol (2012) 1.31
Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids. Arch Virol (1977) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
[Borna virus infection (Borna disease) in naturally and experimentally infected animals: its significance for research and practice]. Tierarztl Prax (1985) 1.29
Behavior alterations in tree shrews (Tupaia glis, Diard 1820) induced by Borna disease virus. Med Microbiol Immunol (1978) 1.29
Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function. J Virol (1991) 1.28
Analysis of herpes simplex virus type 1 antigens exposed on the surface of infected tissue culture cells. Virology (1978) 1.28
Lymphocyte antigen Leu-19 as a molecular marker of regeneration in human skeletal muscle. Proc Natl Acad Sci U S A (1989) 1.27
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer (1994) 1.25
Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion (2001) 1.24
The characterization of Varicella-zoster virus DNA. J Gen Virol (1972) 1.23
Adaptation of Borna disease virus to the mouse. J Gen Virol (1984) 1.23
Human infections with Borna disease virus: seroprevalence in patients with chronic diseases and healthy individuals. J Med Virol (1992) 1.22
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia (2006) 1.22
Increase of virus yields and releases of Borna disease virus from persistently infected cells. Virus Res (1985) 1.20
Natural Borna disease in domestic animals others than horses and sheep. Zentralbl Veterinarmed B (1993) 1.18
[Autoimmune phenomena in D-penicillamine therapy]. Acta Med Austriaca (1975) 1.17
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17
Isolation and characterization of a 14500 molecular weight protein from brains and tissue cultures persistently infected with borna disease virus. J Gen Virol (1985) 1.17
Characterization of an 8-lipoxygenase activity induced by the phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate in mouse skin in vivo. J Biol Chem (1991) 1.17
Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet (2000) 1.17
Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology (1993) 1.16
Learning deficiencies in Borna disease virus-infected but clinically healthy rats. Biol Psychiatry (1989) 1.15
Sequence characterization of human Borna disease virus. Virus Res (1996) 1.15
Inhibition of herpes virus-induced cell fusion by concanavalin A, antisera, and 2-deoxy-D-glucose. J Virol (1974) 1.14
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone (1996) 1.14
Borna disease in rhesus monkeys as a models for uveo-cerebral symptoms. J Med Virol (1981) 1.13
[Surface structure of the human placenta in the scanning electron microscope]. Arch Gynakol (1971) 1.12
Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death Differ (2006) 1.11
Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol (2008) 1.09
Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem (1998) 1.09
[Anticoagulants in the radiotherapy of genital carcinomas in women. I. Squamous cell carcinoma]. Med Welt (1968) 1.09
The effect of caffeine on human performance, alone and in combination with ethanol. Psychopharmacologia (1975) 1.08
Humoral immunodeficiency to bacterial antigens in patients with juvenile onset diabetes mellitus. Diabetologia (1976) 1.08
Personal best marathon performance is associated with performance in a 24-h run and not anthropometry or training volume. Br J Sports Med (2008) 1.06
Fluorosugars inhibit biological properties of different enveloped viruses. J Virol (1976) 1.06
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol (2010) 1.04
Analysis of bovine cytomegalovirus genome structure: cloning and mapping of the monomeric polyrepetitive DNA unit, and comparison of European and American strains. J Gen Virol (1985) 1.04
Bovine cytomegaloviruses: identification and differential properties. J Gen Virol (1984) 1.04
[Ultrastructure of the luminal surface of Fallopian tube in the scanning electron microscope]. Arch Gynakol (1972) 1.04
Borna disease virus-specific circulating immune complexes, antigenemia, and free antibodies--the key marker triplet determining infection and prevailing in severe mood disorders. Mol Psychiatry (2001) 1.04
Short repeats cause heterogeneity at genomic terminus of bovine herpesvirus 1. J Virol (1986) 1.03
Borna virus infections in cattle associated with fatal neurological disease. Vet Rec (1994) 1.03
Bovine herpesvirus 1: differentiation of IBR- and IPV-viruses and identification and functional role of their major immunogenic components. Arch Virol (1985) 1.03
Staggering disease in cats: isolation and characterization of the feline Borna disease virus. J Gen Virol (1995) 1.02
A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians. Neurogastroenterol Motil (2008) 1.02
[Smoking and the risk of cancer]. Wien Med Wochenschr (1994) 1.02
A novel marker for Borna disease virus infection. Lancet (1994) 1.02
Demonstration of specific antibodies in the central nervous system of horses naturally infected with Borna disease virus. Med Microbiol Immunol (1977) 1.01
Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol (2009) 1.00
Focus-immunoassay for Borna disease virus-specific antigens. Zentralbl Veterinarmed B (1984) 1.00
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia (2007) 0.99
Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology (1999) 0.99
Rabies and borna disease. A comparative pathogenetic study of two neurovirulent agents. Lab Invest (1993) 0.99
Formation of new muscle fibres and tumours after injection of cultured myogenic cells. J Neurocytol (1991) 0.99
Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry (1992) 0.98